MAPT and Alzheimer disease: To this end, recent studies have demonstrated the possibility to subdivide AD patients into different clusters based on the CSF levels of a set of potential biomarkers (including Aβ1−42, tau and ubiquitin), demonstrating that each cluster was associated with a different clinical profile and thus potentially different disease-related trajectories and drug responses [36,37,54] (Table 1).